التفاصيل البيبلوغرافية
| العنوان: |
Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer |
| المؤلفون: |
Yu Hu, Xiaohan Lou, Kaili Zhang, Longze Pan, Yueyue Bai, Linlin Wang, Ming Wang, Yan Yan, Jiajia Wan, Xiaohan Yao, Xixi Duan, Chen Ni, Zhihai Qin |
| المصدر: |
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-22 (2024) |
| بيانات النشر: |
BMC, 2024. |
| سنة النشر: |
2024 |
| المجموعة: |
LCC:Medicine |
| مصطلحات موضوعية: |
Triple negative breast cancer, Paclitaxel, Chemoresistance, Endothelial cells, CD8+ T cells, TNFR2, Medicine |
| الوصف: |
Abstract Background T cells play a pivotal role in chemotherapy-triggered anti-tumor effects. Emerging evidence underscores the link between impaired anti-tumor immune responses and resistance to paclitaxel therapy in triple-negative breast cancer (TNBC). Tumor-related endothelial cells (ECs) have potential immunoregulatory activity. However, how ECs regulate T cell activity during TNBC chemotherapy remains poorly understood. Methods Single-cell analysis of ECs in patients with TNBC receiving paclitaxel therapy was performed using an accessible single-cell RNA sequencing (scRNA-seq) dataset to identify key EC subtypes and their immune characteristics. An integrated analysis of a tumor-bearing mouse model, immunofluorescence, and a spatial transcriptome dataset revealed the spatial relationship between ECs, especially Tumor necrosis factor receptor (TNFR) 2+ ECs, and CD8+ T cells. RNA sequencing, CD8+ T cell proliferation assays, flow cytometry, and bioinformatic analyses were performed to explore the immunosuppressive function of TNFR2 in ECs. The downstream metabolic mechanism of TNFR2 was further investigated using RNA sequencing, cellular glycolysis assays, and western blotting. Results In this study, we identified an immunoregulatory EC subtype, characterized by enhanced TNFR2 expression in non-responders. By a mouse model of TNBC, we revealed a dynamic reduction in the proportion of the CD8+ T cell-contacting tumor vessels that could co-localize spatially with CD8+ T cells during chemotherapy and an increased expression of TNFR2 by ECs. TNFR2 suppresses glycolytic activity in ECs by activating NF-κB signaling in vitro. Tuning endothelial glycolysis enhances programmed death-ligand (PD-L) 1-dependent inhibitory capacity, thereby inducing CD8+ T cell suppression. In addition, TNFR2+ ECs showed a greater spatial affinity for exhausted CD8+ T cells than for non-exhausted CD8+ T cells. TNFR2 blockade restores impaired anti-tumor immunity in vivo, leading to the loss of PD-L1 expression by ECs and enhancement of CD8+ T cell infiltration into the tumors. Conclusions These findings reveal the suppression of CD8+ T cells by ECs in chemoresistance and indicate the critical role of TNFR2 in driving the immunosuppressive capacity of ECs via tuning glycolysis. Targeting endothelial TNFR2 may serve as a potent strategy for treating TNBC with paclitaxel. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1479-5876 |
| Relation: |
https://doaj.org/toc/1479-5876 |
| DOI: |
10.1186/s12967-024-05472-5 |
| URL الوصول: |
https://doaj.org/article/ac72a1f9017141b08ea703b5259b4d88 |
| رقم الانضمام: |
edsdoj.72a1f9017141b08ea703b5259b4d88 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder